Integra LifeSciences Holdings Corporation (IART)
Nasdaq · Healthcare · Medical Devices
$13.29+4.81%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.0B
- Forward P/E
- 5.1
- 52-week range
- $8.70 – $20.49
- 52-week change
- −12.13%
- EPS (trailing)
- −$0.09
- Analyst rating
- 2.7 Hold
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $1.6B (+1.53%)
- Net income
- −$517M
- Operating margin
- −30.2%
- Diluted EPS
- −$6.74
- Free cash flow
- −$31.1M
From the company’s annual report on SEC EDGAR.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products.
Headquarters: Princeton, United States · 4,427 employees · integralife.com